Skip to main content
. 2023 Jan 18;15(3):600. doi: 10.3390/cancers15030600

Figure 5.

Figure 5

Figure 5

Subgroup analyses based on neoadjuvant immune checkpoint inhibitor combinations for (A) pCR, (B) MPR, and (C) Grade 3−4 TRAEs. ICI: immune checkpoint inhibitor; pCR: pathological complete response; MPR: major pathological response; TRAEs: treatment-related adverse events [31,32,33,34,35,36,37,38].